middle.news
How Will Anteris’ A$38.5M Raise Accelerate DurAVR®’s Global Trial and Launch?
12:21pm on Tuesday 28th of October, 2025 AEDT
•
Healthcare
Read Story
How Will Anteris’ A$38.5M Raise Accelerate DurAVR®’s Global Trial and Launch?
12:21pm on Tuesday 28th of October, 2025 AEDT
Key Points
A$38.5 million raised via private placement with attached warrants
Funds to support PARADIGM pivotal trial and global commercialization
DurAVR® device designed to mimic healthy aortic valve hemodynamics
FDA IDE submission underway with trial sites planned across multiple countries
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Anteris Technologies Global (ASX:AVR)
OPEN ARTICLE